 | • レポートコード：MRC2-11QY12503 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は白血病治療のグローバル市場について調査・分析したレポートです。種類別（誘導療法、強化療法、維持療法）市場規模、用途別（がん研究センター、診断研究所、クリニック、病院）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別白血病治療の競争状況、市場シェア ・世界の白血病治療市場：種類別市場規模 2015年-2020年（誘導療法、強化療法、維持療法） ・世界の白血病治療市場：種類別市場規模予測 2021年-2026年（誘導療法、強化療法、維持療法） ・世界の白血病治療市場：用途別市場規模 2015年-2020年（がん研究センター、診断研究所、クリニック、病院） ・世界の白血病治療市場：用途別市場規模予測 2021年-2026年（がん研究センター、診断研究所、クリニック、病院） ・北米の白血病治療市場分析：米国、カナダ ・ヨーロッパの白血病治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの白血病治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の白血病治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの白血病治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Genzyme、Novartis International、Pfizer、Roche Holding、Celgene Corporation、Ariad Pharmaceuticals、Clavis Pharma、Sunesis Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Leukemia is a type of cancer which is formed in blood tissues. Leukemia occurs in bone marrow which is a soft tissue. Leukemia develops by the uncontrolled growth of blood cells in the bone marrow. Leukemia is also defined as a cancer of white blood cells. Leukemia therapeutics consists of three steps including induction therapy, consolidation therapy and maintenance therapy.
In recent time there is increased use of leukemia therapeutic due to rising number of cancer diseases across the world. Rising aging population, lifestyle factors and increasing awareness for healthcare are some of the key driving factors for the growth of the global leukemia therapeutics market. In addition, innovative and targeted drug delivery is also fuelling the growth of the global leukemia therapeutics market. However, availability of large numbers of generic form of drugs and limited treatment options are some of the major factors restraining the growth of the global leukemia therapeutics market. In addition, high unmet need for diagnosis is also restraining the growth of the global leukemia therapeutics market.
Market Analysis and Insights: Global Leukemia Therapeutic Market
The global Leukemia Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Leukemia Therapeutic Scope and Market Size
Leukemia Therapeutic market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Leukemia Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Genzyme
Novartis International
Pfizer
Roche Holding
Celgene Corporation
Ariad Pharmaceuticals
Clavis Pharma
Sunesis Pharmaceuticals
Market segment by Type, the product can be split into
Induction Therapy
Consolidation Therapy
Maintenance Therapy
Market segment by Application, split into
Cancer Research Centers
Diagnostic Laboratories
Clinics
Hospitals
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Leukemia Therapeutic Revenue
1.4 Market by Type
1.4.1 Global Leukemia Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Induction Therapy
1.4.3 Consolidation Therapy
1.4.4 Maintenance Therapy
1.5 Market by Application
1.5.1 Global Leukemia Therapeutic Market Share by Application: 2020 VS 2026
1.5.2 Cancer Research Centers
1.5.3 Diagnostic Laboratories
1.5.4 Clinics
1.5.5 Hospitals
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Leukemia Therapeutic Market Perspective (2015-2026)
2.2 Global Leukemia Therapeutic Growth Trends by Regions
2.2.1 Leukemia Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Leukemia Therapeutic Historic Market Share by Regions (2015-2020)
2.2.3 Leukemia Therapeutic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Leukemia Therapeutic Market Growth Strategy
2.3.6 Primary Interviews with Key Leukemia Therapeutic Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Leukemia Therapeutic Players by Market Size
3.1.1 Global Top Leukemia Therapeutic Players by Revenue (2015-2020)
3.1.2 Global Leukemia Therapeutic Revenue Market Share by Players (2015-2020)
3.1.3 Global Leukemia Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Leukemia Therapeutic Market Concentration Ratio
3.2.1 Global Leukemia Therapeutic Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Leukemia Therapeutic Revenue in 2019
3.3 Leukemia Therapeutic Key Players Head office and Area Served
3.4 Key Players Leukemia Therapeutic Product Solution and Service
3.5 Date of Enter into Leukemia Therapeutic Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Leukemia Therapeutic Historic Market Size by Type (2015-2020)
4.2 Global Leukemia Therapeutic Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Leukemia Therapeutic Market Size by Application (2015-2020)
5.2 Global Leukemia Therapeutic Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Leukemia Therapeutic Market Size (2015-2020)
6.2 Leukemia Therapeutic Key Players in North America (2019-2020)
6.3 North America Leukemia Therapeutic Market Size by Type (2015-2020)
6.4 North America Leukemia Therapeutic Market Size by Application (2015-2020)
7 Europe
7.1 Europe Leukemia Therapeutic Market Size (2015-2020)
7.2 Leukemia Therapeutic Key Players in Europe (2019-2020)
7.3 Europe Leukemia Therapeutic Market Size by Type (2015-2020)
7.4 Europe Leukemia Therapeutic Market Size by Application (2015-2020)
8 China
8.1 China Leukemia Therapeutic Market Size (2015-2020)
8.2 Leukemia Therapeutic Key Players in China (2019-2020)
8.3 China Leukemia Therapeutic Market Size by Type (2015-2020)
8.4 China Leukemia Therapeutic Market Size by Application (2015-2020)
9 Japan
9.1 Japan Leukemia Therapeutic Market Size (2015-2020)
9.2 Leukemia Therapeutic Key Players in Japan (2019-2020)
9.3 Japan Leukemia Therapeutic Market Size by Type (2015-2020)
9.4 Japan Leukemia Therapeutic Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Leukemia Therapeutic Market Size (2015-2020)
10.2 Leukemia Therapeutic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Leukemia Therapeutic Market Size by Type (2015-2020)
10.4 Southeast Asia Leukemia Therapeutic Market Size by Application (2015-2020)
11 India
11.1 India Leukemia Therapeutic Market Size (2015-2020)
11.2 Leukemia Therapeutic Key Players in India (2019-2020)
11.3 India Leukemia Therapeutic Market Size by Type (2015-2020)
11.4 India Leukemia Therapeutic Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Leukemia Therapeutic Market Size (2015-2020)
12.2 Leukemia Therapeutic Key Players in Central & South America (2019-2020)
12.3 Central & South America Leukemia Therapeutic Market Size by Type (2015-2020)
12.4 Central & South America Leukemia Therapeutic Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Genzyme
13.1.1 Genzyme Company Details
13.1.2 Genzyme Business Overview
13.1.3 Genzyme Leukemia Therapeutic Introduction
13.1.4 Genzyme Revenue in Leukemia Therapeutic Business (2015-2020))
13.1.5 Genzyme Recent Development
13.2 Novartis International
13.2.1 Novartis International Company Details
13.2.2 Novartis International Business Overview
13.2.3 Novartis International Leukemia Therapeutic Introduction
13.2.4 Novartis International Revenue in Leukemia Therapeutic Business (2015-2020)
13.2.5 Novartis International Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Leukemia Therapeutic Introduction
13.3.4 Pfizer Revenue in Leukemia Therapeutic Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Roche Holding
13.4.1 Roche Holding Company Details
13.4.2 Roche Holding Business Overview
13.4.3 Roche Holding Leukemia Therapeutic Introduction
13.4.4 Roche Holding Revenue in Leukemia Therapeutic Business (2015-2020)
13.4.5 Roche Holding Recent Development
13.5 Celgene Corporation
13.5.1 Celgene Corporation Company Details
13.5.2 Celgene Corporation Business Overview
13.5.3 Celgene Corporation Leukemia Therapeutic Introduction
13.5.4 Celgene Corporation Revenue in Leukemia Therapeutic Business (2015-2020)
13.5.5 Celgene Corporation Recent Development
13.6 Ariad Pharmaceuticals
13.6.1 Ariad Pharmaceuticals Company Details
13.6.2 Ariad Pharmaceuticals Business Overview
13.6.3 Ariad Pharmaceuticals Leukemia Therapeutic Introduction
13.6.4 Ariad Pharmaceuticals Revenue in Leukemia Therapeutic Business (2015-2020)
13.6.5 Ariad Pharmaceuticals Recent Development
13.7 Clavis Pharma
13.7.1 Clavis Pharma Company Details
13.7.2 Clavis Pharma Business Overview
13.7.3 Clavis Pharma Leukemia Therapeutic Introduction
13.7.4 Clavis Pharma Revenue in Leukemia Therapeutic Business (2015-2020)
13.7.5 Clavis Pharma Recent Development
13.8 Sunesis Pharmaceuticals
13.8.1 Sunesis Pharmaceuticals Company Details
13.8.2 Sunesis Pharmaceuticals Business Overview
13.8.3 Sunesis Pharmaceuticals Leukemia Therapeutic Introduction
13.8.4 Sunesis Pharmaceuticals Revenue in Leukemia Therapeutic Business (2015-2020)
13.8.5 Sunesis Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Leukemia Therapeutic Key Market Segments
Table 2. Key Players Covered: Ranking by Leukemia Therapeutic Revenue
Table 3. Ranking of Global Top Leukemia Therapeutic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Leukemia Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Induction Therapy
Table 6. Key Players of Consolidation Therapy
Table 7. Key Players of Maintenance Therapy
Table 8. Global Leukemia Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Leukemia Therapeutic Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Leukemia Therapeutic Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Leukemia Therapeutic Market Share by Regions (2015-2020)
Table 12. Global Leukemia Therapeutic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Leukemia Therapeutic Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Leukemia Therapeutic Market Growth Strategy
Table 18. Main Points Interviewed from Key Leukemia Therapeutic Players
Table 19. Global Leukemia Therapeutic Revenue by Players (2015-2020) (Million US$)
Table 20. Global Leukemia Therapeutic Market Share by Players (2015-2020)
Table 21. Global Top Leukemia Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leukemia Therapeutic as of 2019)
Table 22. Global Leukemia Therapeutic by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Leukemia Therapeutic Product Solution and Service
Table 25. Date of Enter into Leukemia Therapeutic Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Leukemia Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 28. Global Leukemia Therapeutic Market Size Share by Type (2015-2020)
Table 29. Global Leukemia Therapeutic Revenue Market Share by Type (2021-2026)
Table 30. Global Leukemia Therapeutic Market Size Share by Application (2015-2020)
Table 31. Global Leukemia Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 32. Global Leukemia Therapeutic Market Size Share by Application (2021-2026)
Table 33. North America Key Players Leukemia Therapeutic Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Leukemia Therapeutic Market Share (2019-2020)
Table 35. North America Leukemia Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 36. North America Leukemia Therapeutic Market Share by Type (2015-2020)
Table 37. North America Leukemia Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 38. North America Leukemia Therapeutic Market Share by Application (2015-2020)
Table 39. Europe Key Players Leukemia Therapeutic Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Leukemia Therapeutic Market Share (2019-2020)
Table 41. Europe Leukemia Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Leukemia Therapeutic Market Share by Type (2015-2020)
Table 43. Europe Leukemia Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Leukemia Therapeutic Market Share by Application (2015-2020)
Table 45. China Key Players Leukemia Therapeutic Revenue (2019-2020) (Million US$)
Table 46. China Key Players Leukemia Therapeutic Market Share (2019-2020)
Table 47. China Leukemia Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 48. China Leukemia Therapeutic Market Share by Type (2015-2020)
Table 49. China Leukemia Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 50. China Leukemia Therapeutic Market Share by Application (2015-2020)
Table 51. Japan Key Players Leukemia Therapeutic Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Leukemia Therapeutic Market Share (2019-2020)
Table 53. Japan Leukemia Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Leukemia Therapeutic Market Share by Type (2015-2020)
Table 55. Japan Leukemia Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Leukemia Therapeutic Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Leukemia Therapeutic Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Leukemia Therapeutic Market Share (2019-2020)
Table 59. Southeast Asia Leukemia Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Leukemia Therapeutic Market Share by Type (2015-2020)
Table 61. Southeast Asia Leukemia Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Leukemia Therapeutic Market Share by Application (2015-2020)
Table 63. India Key Players Leukemia Therapeutic Revenue (2019-2020) (Million US$)
Table 64. India Key Players Leukemia Therapeutic Market Share (2019-2020)
Table 65. India Leukemia Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 66. India Leukemia Therapeutic Market Share by Type (2015-2020)
Table 67. India Leukemia Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 68. India Leukemia Therapeutic Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Leukemia Therapeutic Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Leukemia Therapeutic Market Share (2019-2020)
Table 71. Central & South America Leukemia Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Leukemia Therapeutic Market Share by Type (2015-2020)
Table 73. Central & South America Leukemia Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Leukemia Therapeutic Market Share by Application (2015-2020)
Table 75. Genzyme Company Details
Table 76. Genzyme Business Overview
Table 77. Genzyme Product
Table 78. Genzyme Revenue in Leukemia Therapeutic Business (2015-2020) (Million US$)
Table 79. Genzyme Recent Development
Table 80. Novartis International Company Details
Table 81. Novartis International Business Overview
Table 82. Novartis International Product
Table 83. Novartis International Revenue in Leukemia Therapeutic Business (2015-2020) (Million US$)
Table 84. Novartis International Recent Development
Table 85. Pfizer Company Details
Table 86. Pfizer Business Overview
Table 87. Pfizer Product
Table 88. Pfizer Revenue in Leukemia Therapeutic Business (2015-2020) (Million US$)
Table 89. Pfizer Recent Development
Table 90. Roche Holding Company Details
Table 91. Roche Holding Business Overview
Table 92. Roche Holding Product
Table 93. Roche Holding Revenue in Leukemia Therapeutic Business (2015-2020) (Million US$)
Table 94. Roche Holding Recent Development
Table 95. Celgene Corporation Company Details
Table 96. Celgene Corporation Business Overview
Table 97. Celgene Corporation Product
Table 98. Celgene Corporation Revenue in Leukemia Therapeutic Business (2015-2020) (Million US$)
Table 99. Celgene Corporation Recent Development
Table 100. Ariad Pharmaceuticals Company Details
Table 101. Ariad Pharmaceuticals Business Overview
Table 102. Ariad Pharmaceuticals Product
Table 103. Ariad Pharmaceuticals Revenue in Leukemia Therapeutic Business (2015-2020) (Million US$)
Table 104. Ariad Pharmaceuticals Recent Development
Table 105. Clavis Pharma Company Details
Table 106. Clavis Pharma Business Overview
Table 107. Clavis Pharma Product
Table 108. Clavis Pharma Revenue in Leukemia Therapeutic Business (2015-2020) (Million US$)
Table 109. Clavis Pharma Recent Development
Table 110. Sunesis Pharmaceuticals Business Overview
Table 111. Sunesis Pharmaceuticals Product
Table 112. Sunesis Pharmaceuticals Company Details
Table 113. Sunesis Pharmaceuticals Revenue in Leukemia Therapeutic Business (2015-2020) (Million US$)
Table 114. Sunesis Pharmaceuticals Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Leukemia Therapeutic Market Share by Type: 2020 VS 2026
Figure 2. Induction Therapy Features
Figure 3. Consolidation Therapy Features
Figure 4. Maintenance Therapy Features
Figure 5. Global Leukemia Therapeutic Market Share by Application: 2020 VS 2026
Figure 6. Cancer Research Centers Case Studies
Figure 7. Diagnostic Laboratories Case Studies
Figure 8. Clinics Case Studies
Figure 9. Hospitals Case Studies
Figure 10. Leukemia Therapeutic Report Years Considered
Figure 11. Global Leukemia Therapeutic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Leukemia Therapeutic Market Share by Regions: 2020 VS 2026
Figure 13. Global Leukemia Therapeutic Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Leukemia Therapeutic Market Share by Players in 2019
Figure 16. Global Top Leukemia Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leukemia Therapeutic as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Leukemia Therapeutic Revenue in 2019
Figure 18. North America Leukemia Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Leukemia Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Leukemia Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Leukemia Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Leukemia Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Leukemia Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Leukemia Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
白血病の世界市場（～2026年） Leukemia is a group ofcancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells. High incidence rate of blood cancers and rise in incidence of leukaemia across the globe will drive the leukemia market. Market Analysis and Insights: Global Leukemia Cancer …- 急性骨髄性白血病の世界市場（～2026年） Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical …
- 白血病スクリーニングの世界市場（～2026年） Currently, there are no standard leukemia screening methods recommended for regularly testing the leukemia affected patients. Specifically, no leukemia screening test has been reliably confirmed enough to detect the cancer in its early stages before the development of symptoms. Research and developm…
- 乳癌治療の世界市場（～2026年） Market Analysis and Insights: Global Breast Cancer Therapeutic Market The global Breast Cancer Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Breast Cancer Therapeutic Scope and Market Size Breast Cancer T…
- 白血病治療薬の世界市場（～2026年） Leukemia Treatment Drugs is used to cure Leukemia. Increasing geriatric population base and high unmet needs regarding early diagnosis and treatment of leukemia are the key factors driving the leukemia therapeutics market. Market Analysis and Insights: Global Leukemia Treatment Drugs Market The glob…